Monitoring Neutrophil to Lymphocyte Ratio in COVID-19 Patients Receiving Tocilizumab

The novel coronavirus disease (COVID-19) is an infectious disease caused by SARS-CoV-2, an enveloped non-segmented positive-sense RNA β-coronavirus. The virus can trigger a cascade of biological events that can lead to critical illness. It is urgent to gain an in-depth understanding of the critical activators that foreshadow patients highest risk for mortality.(1) Patients who have received tocilizumab for COVID-19 related cytoki ne storm have had improvements in c-reactive protein (CRP), lymphocytosis, and chest CT findings.(2) There exist a lack of understanding on which patients would benefit from Tocilizumab administration.

Source: Annals of Allergy, Asthma and Immunology - December 29, 2020 Category: Allergy & Immunology Authors: Nicholas L. Hartog, Alan T. Davis, Jeremy W. Prokop, Andrew Walls, Surender Rajasekaran Tags: Letters Source Type: research